



7-14-04

IFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/750,570
	Filing Date	December 30, 2003
	First Named Inventor	Reddy, Satyanarayana G.
	Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	60188CON2(49947)
Total Number of Pages in This Submission		1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks Form PTO/SB/08a/b (3 pages); Certificate of Express Mailing (1 page); Information Disclosure Statement (2 pages, in duplicate); Copies of references A18, A19 and B4; Transmittal (1 page) and; Return Receipt Postcard		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	EDWARDS & ANGELL, LLP Peter C. Lauro - 32,360
Signature	
Date	July 12, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 43896 9489 US, in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on the date shown below.	
Dated: July 12, 2004	Signature: (Peter C. Lauro, Esq.)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 438969489 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 12, 2004

Signature: 

(Peter C. Lauro, Esq.)

Docket No.: 60188CON2(49947)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Reddy, Satyanarayana G.

Application No.: 10/750570

Confirmation No.: 5725

Filed: December 30, 2003

Art Unit: 1614

For: Cyclic Ether Vitamin D3 Compounds,
1 α (OH)3-EPI-Vitamin D3 Compounds and
Uses Thereof

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56 and 1.97, Applicant hereby invites the Examiner's attention to the references listed on the attached form PTO/SB/08, in connection with the examination of the above-identified patent application. Applicant respectfully requests that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This application is a continuation application of application serial no. 10/188,320, filed on July 1, 2002, abandoned, which is a continuation application of serial no. 09/617,881, filed on July 17, 2000, issued as U.S. Patent 6,479,538, which is a divisional application of application serial no. 09/079,942, filed on May 15, 1998, issued as U.S. Patent 6,100,294, which in turn claims priority to provisional application serial no. 60/046,690, filed on May 16, 1997.

Copies of references A18, A19 and B4 listed on the PTO/SB/08 are enclosed.

Pursuant to 37 C.F.R. §1.98(d), copies of the remaining references listed on the PTO/SB/08 are

not enclosed because these references were submitted to, or cited by, the Office in information disclosure statements filed in one or more of the above-identified priority applications, and those statements complied with paragraphs (a)-(c) of 37 C.F.R. §1.98

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 C.F.R. §1.17(p) to our Deposit Order Account No. 04-1105. A duplicate of this statement is enclosed.

Dated: July 12, 2004


Respectfully submitted,

By 

Peter C. Lauro, Esq.

Registration No.: 32,360
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 439-4444
Attorney for Applicant

Customer No.: 21874



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/750570
				Filing Date	December 30, 2003
				First Named Inventor	Reddy, Satyanarayana G.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	60188CON2(49947)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	4,021,423	05/77	Baggiolini et al.	
	A2	4,038,272	07/77	Partridge, Jr. et al.	
	A3	4,188,345	08/80	DeLuca et al.	
	A4	4,206,131	06/80	Salmond	
	A5	4,595,776	06/86	Baggiolini et al.	
	A6	4,711,881	12/87	Ikekawa	
	A7	4,804,502	02/89	Baggiolini et al.	
	A8	5,145,846	06/92	Baggiolini, deceased et al.	
	A9	5,206,229	04/93	Calverley et al.	
	A10	5,206,230	04/93	Ikekawa et al.	
	A11	5,389,622	02/95	Posner et al.	
	A12	5,401,733	03/95	McLane et al.	
	A13	5,428,029	06/95	Doran et al.	
	A14	5,547,947	08/96	Dore et al.	
	A15	5,789,607	08/98	Okabe	
	A16	5,824,811	10/98	Kubodera et al.	
	A17	5,830,885	11/98	Posner	
	A18	6,100,294	08/00	S.G. Reddy	
	A19	6,479,538	11/02	S.G. Reddy	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP 808,831	11/97			
	B2	EP 808,833	11/97			
	B3	FR 2545824 A	11/84			
	B4	AU 743514	05/02	S.G. Reddy		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Baggiolini, E. et al., "Stereocontrolled Total Synthesis of 1 α ,25-Dihydroxycholecalciferol and 1 α ,25-Dihydroxyergocalciferol," <i>J. Org. Chem.</i> 51:3098-3108 (1986)	
	C2	Bishop, J. et al., "Profile of Ligand Specificity of the Vitamin D Binding Protein for 1 α ,25-Dihydroxyvitamin D ₃ and its Analogs," <i>J. Bone & Mineral Res.</i> 9(8): 1277-88 (1994)	

Examiner Signature	/Taofiq Solola/	Date Considered	11/17/2008
--------------------	-----------------	-----------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/750570
				Filing Date	December 30, 2003
				First Named Inventor	Reddy, Satyanarayana G.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	60188CON2(49947)

C3	Bouillon, R. et al., "Biologic Activity of Dihydroxylated 19-Nor-(Pre) Vitamin D ₃ ," <i>J. Bone & Mineral Res.</i> 8(8):1009-15 (1993)
C4	Bouillon, R. et al., "Structure-Function Relationships in the Vitamin D Endocrine System," <i>Endocrine Reviews</i> 16(2): 200-57 (1995)
C5	Campbell, M. et al., "Vitamin D ₃ Analogs and Their 24-Oxo Metabolites Equally Inhibit Clonal Proliferation of a Variety of Cancer Cells but Have Differing Molecular Effects," <i>J. Cellular Biochem.</i> 66:413-25 (1997)
C6	Cota, J.G. et al. "Hydroxylation-Protonation of Vitamin D ₂ and Its Analogues: An Efficient Method for the Preparation of 10,19-Dihydrovitamins D ₂ Including Dihydrotachysterol ₂ " <i>Journal of Organic Chemistry</i> 53(26):6094- (1988).
C7	Cross, H. et al., "Vitamin D Metabolism in Human Colon Adenocarcinoma-derived Caco-2 Cells: Expression of 25-Hydroxyvitamin D ₃ -1 α -hydroxylase Activity and Regulation of Side-chain Metabolism," <i>J. Steroid Biochem. Molec. Biol.</i> 62(1):21-8 (1997)
C8	de Vos, S. et al., "Effects of Potent Vitamin D ₃ Analogs on Clonal Proliferation of Human Prostate Cancer Cell Lines," <i>The Prostate</i> 31(2):77-83 (1997)
C9	Dusso, A.S. et al., "On the Mechanisms for the Selective Action of Vitamin D Analogs," <i>Endocrinology</i> 128(4):1687-92 (1991)
C10	Fioravanti, L. et al., "Synthetic Analogs of Vitamin D ₃ Have Inhibitory Effects on Breast Cancer Cell Lines," <i>Anticancer Research</i> 18:1703-8 (1998)
C11	Fleet, J. et al., "1 α ,25-(OH) ₂ -Vitamin D ₃ Analogs with Minimal in Vivo Calcemic Activity Can Stimulate Significant Transepithelial Calcium Transport and mRNA Expression in Vitro," <i>Archives of Biochem. & Biophysics</i> 329(2):228-34 (1996)
C12	Fleet, J.C. et al., "Effect of A-Ring Diastereomers of 1 α ,25-Dihydroxy Vitamin D ₃ on Calcium Transport in Caco-2 Cells," <i>FASEB J.</i> 9(3):168 (1995)
C13	Gardner, J. et al., "Vitamin D Analog 25-(OH)-16,23E-Diene-26,27-Hexafluoro-Vitamin D ₃ Induces Differentiation of HL60 Cells with Minimal Effects on Cellular Calcium Homeostasis," <i>J. Cellular Biochem.</i> 63:500-12 (1996)
C14	Jung, S. et al., "1,25(OH) ₂ -16ENE-Vitamin D ₃ is a Potent Antileukemic Agent with Low Potential to Cause Hypercalcemia," <i>Leukemia Research</i> 18(6):453-63 (1994)
C15	Kim, H. et al., "1,25-Dihydroxy-Vitamin-D ₃ Enhances Antiproliferative Effect and Transcription of TGF- β 1 on Human Keratinocytes in Culture," <i>J. Cellular Physiol.</i> 151:579-87 (1992)
C16	Lemire, J. et al., "1,25-Dihydroxy-24-OXO-16ene-Vitamin D ₃ , a Renal Metabolite of the Vitamin D Analog 1,25-Dihydroxy-16ene-vitamin D ₃ , Exerts Immunosuppressive Activity Equal to its Parent Without Causing Hypercalcemia in vivo," <i>Endocrinology</i> 135(6):2818-21 (1994)
C17	Mayer, E. et al., "23,25-Dihydroxy-24-oxovitamin D ₃ : A Metabolite of Vitamin D ₃ Made in the Kidney," <i>Biochemistry</i> 22(8):1798-1805 (1983)
C18	Muralidharan, K.R., "Studies on the A-Ring Diastereomers of 1 α , 25-Dihydroxyvitamin D ₃ ," <i>J. Organic Chem.</i> 58(7):1895-1899 (1993)
C19	Norman, A. et al., "Demonstration That 1 β ,25-Dihydroxyvitamin D ₃ is an Antagonist of the Nongenomic but not Genomic Biological Responses and Biological Profile of the Three A-ring Diastereomers of 1 α ,25-Dihydroxyvitamin D ₃ ," <i>J. Biol. Chem.</i> 268(27):20022-30 (1993)
C20	Okamura, W.H. et al., "Studies on vitamin D (Calciferol) and Its Analogues 13," <i>J. Organic Chem.</i> 43(4):574-580 (1978)

Examiner Signature	/Taofiq Solola/	Date Considered	11/17/2008
--------------------	-----------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/750570
				Filing Date	December 30, 2003
				First Named Inventor	Reddy, Satyanarayana G.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	60188CON2(49947)

	C21	Reddy, G.S. and Tserng, KY, "Calcitriol Acid, End Product of Renal Metabolism of 1,25-Dihydroxyvitamin D ₃ Through C-24 Oxidation Pathway," <i>Biochemistry</i> 28:1763-9 (1989)	
	C22	Reddy, G.S. et al., "Metabolism of 1 α ,25-Dihydroxyvitamin D ₃ and One of its A-Ring Diastereomer 1 α ,25-Dihydroxy-3-Epivitamin D ₃ in Neonatal Human Keratinocytes," <i>Vitamin D: A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications, Proceedings of the Ninth Workshop on Vitamin D</i> , Orlando, FL., 172-3 (May 28-June 2, 1994)	
	C23	Reddy, G.S. et al., "Stimulation of 24R,25-dihydroxyvitamin D ₃ Synthesis by Metabolites of Vitamin D ₃ ," <i>Am. J. Physiol.</i> 245(4):E359-64 (1983)	
	C24	Reddy, G.S. et al., "Study of 1,25-Dihydroxyvitamin D ₃ Induced Alterations in the Metabolism of [³ H]25-Hydroxyvitamin D ₃ Using Isolated Perfused Kidneys From D-Sufficient Rats," <i>Biochem. & Biophys. Res. Commun.</i> 107(3):922-8 (1982)	
	C25	Reichel, H. and Norman, A., "Systemic Effects of Vitamin D," <i>Ann. Rev. Med.</i> 40:71-8 (1989)	
	C26	Scheddin, D. et al., "Synthesis and Biological Activities of 26-Hydroxy-27-Nor-Derivatives of 1- α , 25-Dihydroxyvitamin D ₃ ," <i>Steroids</i> 61(10):598-608 (1996)	
	C27	Schwartz, G. et al., "1,25-Dihydroxy-16-ENE-23-YNE-Vitamin D ₃ and Prostate Cancer Cell Proliferation in Vivo," <i>Urology</i> 46(3):365-9 (1995)	
	C28	Siu-Caldera, ML et al., "The Enhanced Biological Activities Ascribed to its Parent Analog, 1 α ,25(OH) ₂ -16-ene-D ₃ ," <i>J. Steroid Biochem. Molec. Biol.</i> 59(5/6):405-12 (1996)	
	C29	Veyron, P. et al., "New 20-Epi-Vitamin D ₃ Analogs: Immunosuppressive Effects on Skin Allograft Survival," <i>Transplantation Proceedings</i> 27(1):450 (1995)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Taofiq Solola/	Date Considered	11/17/2008
--------------------	-----------------	-----------------	------------



Application No. (if known): 10/750,570

Attorney Docket No.: 60188CON2(49947)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 438969489 US in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 12, 2004
Date

Signature

Peter C. Lauro

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Form PTO/SF/08a/b (3 pages);
Certificate of Express Mailing Under 37 CFR 1.10 (1 page);
Information Disclosure Statement (2 pages, in duplicate);
Copies of references A18, A19 and B4;
Transmittal (1 page) and;
Return Receipt Postcard

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 436969489 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 12, 2004

Signature: *Peter C. Lauro*

(Peter C. Lauro, Esq.)

Docket No.: 60188CON2(49947)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Reddy, Satyanarayana G.

Application No.: 10/750570

Confirmation No.: 5729

Filed: December 30, 2003

Art Unit: 1614

For: Cyclic Ether Vitamin D3 Compounds,
1 α (OH)3-EPI- Vitamin D3 Compounds and
Uses Thereof

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56 and 1.97, Applicant hereby invites the Examiner's attention to the references listed on the attached form PTO/SB/08, in connection with the examination of the above-identified patent application. Applicant respectfully requests that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This application is a continuation application of application serial no. 10/188,320, filed on July 1, 2002, abandoned, which is a continuation application of serial no. 09/617,881, filed on July 17, 2000, issued as U.S. Patent 6,479,538, which is a divisional application of application serial no. 09/079,942, filed on May 15, 1998, issued as U.S. Patent 6,100,294, which in turn claims priority to provisional application serial no. 60/046,690, filed on May 16, 1997.

Copies of references A18, A19 and B4 listed on the PTO/SB/08 are enclosed.

Pursuant to 37 C.F.R. §1.98(d), copies of the remaining references listed on the PTO/SB/08 are

not enclosed because these references were submitted to, or cited by, the Office in information disclosure statements filed in one or more of the above-identified priority applications, and those statements complied with paragraphs (a)-(c) of 37 C.F.R. §1.98

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 C.F.R. §1.17(p) to our Deposit Order Account No. 04-1105. A duplicate of this statement is enclosed.

Dated: July 12, 2004

Respectfully submitted,

By 

Peter C. Laure, Esq.

Registration No.: 32,360

EDWARDS & ANGELL, LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorney for Applicant

Customer No.: 21874